Author

Morten Abildlund Nielsen

Observed names: M Nielsen, M.A. Nielsen, MORTEN ABILDLUND NIELSEN, Morten A Nielsen, Morten A. Nielsen

Observed institution: Novo Nordisk (Denmark)

OpenAlex ID: A5037124337

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

2020 · John B Buse, Bruce W Bode, et al. · BMJ Open Diabetes Research & Care · 39

930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

2020 · CYRUS DESOUZA, ASLAM AMOD, et al. · Diabetes · 4

670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial

2021 · JULIO ROSENSTOCK, BERTRAND CARIOU, et al. · Diabetes · 2

964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program

2020 · KATHLEEN M. DUNGAN, CHRISTIN L. HERTZ, et al. · Diabetes · 2

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program

2022 · Kunal Srivastava, Cyrus Desouza, et al. · Indian Journal of Endocrinology and Metabolism

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial

2022 · Prashanth S Prakash, Julio Rosenstock, et al. · Indian Journal of Endocrinology and Metabolism

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program

2022 · K B Sharan Kumar, Kathleen M Dungan, et al. · Indian Journal of Endocrinology and Metabolism

63 - Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program

2020 · Kathleen Dungan, Christin Løth Hertz, et al. · Canadian Journal of Diabetes

60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

2020 · Cyrus Desouza, Aslam Amod, et al. · Canadian Journal of Diabetes

Efficacy of semaglutide vs. dulaglutide across baseline HbA1c in SUSTAIN 7

2019 · W Schmidt, R Pratley, et al. · Diabetologie und Stoffwechsel

Efficacy of Semaglutide vs. Dulaglutide Across Baseline HbA1C in SUSTAIN 7

2018 · Paulina K. Wrzal, Richard E. Pratley, et al. · Canadian Journal of Diabetes

Efficacité du semaglutide versus dulaglutide en fonction du taux initial d’HbA1c dans l’étude SUSTAIN 7

2018 · B. Guerci, R. Pratley, et al. · Annales d Endocrinologie

Efficacy of Semaglutide vs. Dulaglutide across Baseline HbA1c in SUSTAIN 7

2018 · RICHARD E. PRATLEY, JUAN P. FRIAS, et al. · Diabetes

Works count: 13

Citation count: 47

H-index: 2

I10-index: 1